BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Batiha GE, Al-Gareeb DAI, Qusti S, Alshammari EM, Rotimi D, Adeyemi OS, Al-Kuraishy HM. Common NLRP3 inflammasome inhibitors and Covid-19: Divide and Conquer. Sci Afr 2021;:e01084. [PMID: 34957352 DOI: 10.1016/j.sciaf.2021.e01084] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Alkazmi L, Al-Kuraishy HM, Al-Gareeb AI, El-Bouseary MM, Ahmed EA, Batiha GE. Dantrolene and ryanodine receptors in COVID-19: The daunting task and neglected warden. Clin Exp Pharmacol Physiol 2023. [PMID: 36732880 DOI: 10.1111/1440-1681.13756] [Reference Citation Analysis]
2 Zurita‐lizza CC, Rodriguez‐sanchez I, Doreski PA. Blocking the action of NLRP3 inflammasome by inhaled ibuprofenate on pulmonary macrophages infected by SARS‐CoV‐2. Clinical and Translational Dis 2023;3. [DOI: 10.1002/ctd2.169] [Reference Citation Analysis]
3 Al-Kuraishy HM, Al-Gareeb AI, Kaushik A, Kujawska M, Ahmed EA, Batiha GE. SARS-COV-2 infection and Parkinson's disease: Possible links and perspectives. J Neurosci Res 2023. [PMID: 36717481 DOI: 10.1002/jnr.25171] [Reference Citation Analysis]
4 Al-Kuraishy HM, Al-Gareeb AI, Al-Harcan NAH, Alexiou A, Batiha GE. Tranexamic Acid and Plasminogen/Plasmin Glaring Paradox in COVID-19. Endocr Metab Immune Disord Drug Targets 2023;23:35-45. [PMID: 35927893 DOI: 10.2174/1871530322666220801102402] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Arjmand B, Alavi-Moghadam S, Sarvari M, Rezaei-Tavirani M, Rezazadeh-Mafi A, Arjmand R, Nikandish M, Nasli-Esfahani E, Larijani B. Critical roles of cytokine storm and bacterial infection in patients with COVID-19: therapeutic potential of mesenchymal stem cells. Inflammopharmacology 2023;31:171-206. [PMID: 36600055 DOI: 10.1007/s10787-022-01132-6] [Reference Citation Analysis]
6 Batiha GE, Al-Kuraishy HM, Al-Gareeb AI, Youssef FS, El-Sherbeni SA, Negm WA. A perspective study of the possible impact of obeticholic acid against SARS-CoV-2 infection. Inflammopharmacology 2023;31:9-19. [PMID: 36484974 DOI: 10.1007/s10787-022-01111-x] [Reference Citation Analysis]
7 Albogami SM, Al-Kuraishy HM, Al-Maiahy TJ, Al-Buhadily AK, Al-Gareeb AI, Alorabi M, Alotaibi SS, De Waard M, Sabatier JM, Saad HM, Batiha GE. Hypoxia-Inducible Factor 1 and Preeclampsia: A New Perspective. Curr Hypertens Rep 2022;24:687-92. [PMID: 36342613 DOI: 10.1007/s11906-022-01225-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Cao JF, Gong Y, Wu M, Xiong L, Chen S, Huang H, Zhou X, Peng YC, Shen XF, Qu J, Wang YL, Zhang X. Molecular docking and molecular dynamics study Lianhua Qingwen granules (LHQW) treats COVID-19 by inhibiting inflammatory response and regulating cell survival. Front Cell Infect Microbiol 2022;12:1044770. [PMID: 36506032 DOI: 10.3389/fcimb.2022.1044770] [Reference Citation Analysis]
9 Al-Kuraishy HM, Al-Gareeb AI, Mohammed AA, Alexiou A, Papadakis M, Batiha GE. The potential link between Covid-19 and multiple myeloma: A new saga. Immun Inflamm Dis 2022;10:e701. [PMID: 36444620 DOI: 10.1002/iid3.701] [Reference Citation Analysis]
10 Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Batiha GE. Central Effects of Ivermectin in Alleviation of Covid-19-induced Dysauto-nomia. Curr Drug Targets 2022;23:1277-87. [PMID: 35950254 DOI: 10.2174/1389450123666220810102406] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Al-Kuraishy HM, Al-Gareeb AI, Al-Maiahy TJ, Alexiou A, Mukerjee N, Batiha GE. An insight into the placental growth factor (PlGf)/angii axis in Covid-19: a detrimental intersection. Biotechnol Genet Eng Rev 2022;:1-20. [PMID: 36096720 DOI: 10.1080/02648725.2022.2122291] [Reference Citation Analysis]
12 Alkhayyat SS, Al-Kuraishy HM, Al-Gareeb AI, El-Bouseary MM, AboKamer AM, Batiha GE, Simal-Gandara J. Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail. Inflamm Res 2022. [PMID: 35941297 DOI: 10.1007/s00011-022-01615-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Al-Kuraishy HM, Al-Gareeb AI, Al-Niemi MS, Aljowaie RM, Almutairi SM, Alexiou A, Batiha GE. The Prospective Effect of Allopurinol on the Oxidative Stress Index and Endothelial Dysfunction in Covid-19. Inflammation 2022;45:1651-67. [PMID: 35199285 DOI: 10.1007/s10753-022-01648-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 14.0] [Reference Citation Analysis]
14 Al-kuraishy HM, Al-gareeb AI, Al-hamash SM, Cavalu S, El-bouseary MM, Sonbol FI, Batiha GE. Changes in the Blood Viscosity in Patients With SARS-CoV-2 Infection. Front Med 2022;9:876017. [DOI: 10.3389/fmed.2022.876017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Al-Kuraishy HM, Al-Gareeb AI, El-Bouseary MM, Sonbol FI, Batiha GE. Hyperviscosity syndrome in COVID-19 and related vaccines: exploring of uncertainties. Clin Exp Med 2022. [PMID: 35608715 DOI: 10.1007/s10238-022-00836-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Al-Kuraishy HM, Al-Gareeb AI, Al-Hussaniy HA, Al-Harcan NAH, Alexiou A, Batiha GE. Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modality. Int Immunopharmacol 2022;104:108516. [PMID: 35032828 DOI: 10.1016/j.intimp.2021.108516] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 30.0] [Reference Citation Analysis]